A meniscus tear on an MRI does not automatically mean that a patient needs surgery. It also does not always prove that the tear is the main source of knee pain. At Caring Medical, we evaluate the meniscus as one part of a larger load-bearing system that includes the knee ligaments, joint capsule, muscles, articular cartilage, alignment, and movement pattern.
This distinction is important. Some tears follow a clear twisting injury and produce swelling, joint-line pain, catching, or an inability to fully straighten the knee. Others develop gradually as the meniscus and surrounding joint age. Meniscal abnormalities are also common on MRI in adults who have no knee symptoms at all. In a population study of middle-aged and older adults, many meniscal tears were found incidentally, and most people with a tear did not report pain or stiffness during the preceding month. (1)
For this reason, we do not treat an MRI report in isolation. We ask whether the patient’s symptoms, physical examination, injury history, knee stability, and imaging tell a coherent story. When appropriate, nonsurgical care may include activity modification, progressive rehabilitation, weight management, bracing, and—in selected patients—a discussion of injection options such as dextrose Prolotherapy or platelet-rich plasma (PRP).
The evidence needs to be presented honestly. Exercise-based rehabilitation is the best-supported first-line treatment for many degenerative meniscal lesions. Research specifically showing that Prolotherapy heals a torn meniscus is limited. The available evidence is more supportive for improving pain and function in knee osteoarthritis than for proving structural meniscal repair. This article explains where the evidence is strong, where it is promising, and where uncertainty remains.
What is the meniscus, and why does preserving it matter?
Each knee contains two crescent-shaped pads of fibrocartilage: the medial meniscus on the inner side and the lateral meniscus on the outer side. The menisci distribute load, absorb shock, improve the fit between the thighbone and shinbone, assist joint lubrication, and contribute to stability.
The outer portion of a meniscus receives a better blood supply and is often called the “red zone.” The inner “white zone” has little direct blood supply. Tear location is therefore one factor that affects healing, but it is not the only one. Tear pattern, tissue quality, age, alignment, knee stability, activity demands, and associated injuries all matter.
Modern meniscus care emphasizes preservation whenever practical. Removing meniscal tissue reduces the knee’s load-distributing capacity and increases stress on the remaining cartilage. When surgery is necessary, repair is generally preferred over removal when the tear is repairable. A meta-analysis comparing repair with meniscectomy after acute tears found a lower rate of progression to advanced osteoarthritis and knee replacement after repair. (2)
Patients with persistent pain after meniscus removal may also have articular cartilage damage, bone-marrow lesions, synovitis, altered mechanics, or knee instability. The remaining meniscus should not automatically be assumed to be the only pain generator.
Traumatic and degenerative meniscus tears are not the same problem
Traumatic tears
A traumatic tear commonly follows a pivot, deep squat, sudden deceleration, or forceful rotation on a planted foot. These injuries are more common in athletes and younger patients, although they can occur at any age. They may occur with an anterior cruciate ligament (ACL) or collateral-ligament injury.
Certain traumatic tears deserve prompt orthopedic evaluation. These include displaced bucket-handle tears, repairable tears in younger patients, symptomatic root tears, and tears occurring with major ligament injury. A knee that is physically locked—not merely painful or stiff—may contain displaced tissue preventing normal motion.
Degenerative tears
Degenerative tears develop in tissue that has changed over time. They may appear without a memorable injury and often coexist with osteoarthritis. In this setting, the tear can be part of the disease process rather than an isolated defect that needs to be trimmed away.
The 2024 EU-US meniscus rehabilitation consensus, published in 2025, recommends nonoperative treatment including physical therapy as the first-line approach for degenerative meniscal lesions. It also recognizes that nonoperative treatment may be appropriate for selected traumatic tears, depending on tear type, symptoms, and patient factors. (3)
Why an MRI should not make the treatment decision by itself
MRI can identify tear pattern, extrusion, root involvement, cartilage loss, bone-marrow changes, swelling, and ligament injury. It is valuable when the findings are interpreted alongside the clinical examination. However, an MRI cannot by itself determine which structure is causing pain or predict who will respond to a particular treatment.
At Caring Medical, the examination may include joint-line tenderness, range of motion, swelling, gait, alignment, muscle control, and tests for cruciate and collateral-ligament stability. When clinically appropriate, musculoskeletal ultrasound can provide additional information about superficial soft tissues, effusion, and dynamic movement, although MRI remains better suited to viewing the internal meniscus.
We also look beyond the tear. A patient may have pain from osteoarthritis, patellofemoral dysfunction, tendinopathy, synovitis, a Baker’s cyst, referred hip or lumbar pain, or an inflammatory condition. Treating a scan without identifying the dominant pain generator can lead to disappointing results.
Physical therapy versus arthroscopic partial meniscectomy
For many adults with degenerative meniscal tears, structured exercise performs as well as arthroscopic partial meniscectomy over the long term. In the five-year ESCAPE randomized trial, exercise-based physical therapy remained noninferior to surgery for patient-reported knee function, supporting physical therapy as the preferred treatment for degenerative tears. (4)
A 2024 meta-analysis of randomized trials likewise found no clinically meaningful long-term advantage of arthroscopic partial meniscectomy over exercise therapy for pain or function in degenerative tears. (5) Placebo-controlled research has also shown that arthroscopic partial meniscectomy did not provide a significant benefit over sham surgery for degenerative meniscal tears in patients without knee osteoarthritis. (6)
These findings do not mean that meniscus surgery is never appropriate. Surgery may be reasonable when there is a repairable acute tear, displaced fragment, true mechanical block, root tear, significant associated injury, or persistent disabling symptoms after a well-designed nonsurgical program. The decision should account for the patient’s age, goals, tear morphology, arthritis severity, alignment, and joint stability.
Readers considering an operation may also find our discussion of surgical and nonsurgical treatment for meniscus tears helpful.
Our clinical perspective: the meniscus is part of a stability system
At Caring Medical, we often see patients whose knee pain is accompanied by looseness, recurrent swelling, giving way, or pain during loading and direction changes. In these patients, we assess whether ligament laxity or altered mechanics may be increasing stress across the meniscus.
The meniscus works with the ACL, posterior cruciate ligament, collateral ligaments, capsule, muscles, and joint surfaces. If this system does not control motion well, simply focusing on a meniscal MRI finding may miss a clinically important contributor. Our treatment goal is therefore not to promise that an injection will “regrow” a meniscus. It is to identify the painful and unstable structures that may be amenable to treatment and to improve the environment in which the knee functions.
This approach may include strengthening, movement retraining, modification of aggravating loads, and treatment of associated ACL injury or medial collateral ligament injury when present.
What is Prolotherapy?
Prolotherapy is an injection treatment most commonly using a concentrated dextrose solution. Depending on the diagnosis and technique, injections may be placed into painful ligament or tendon attachments, around the joint, or into the joint. The proposed goals include stimulating a local healing response, reducing pain, and improving the function of injured connective tissues.
Prolotherapy is not the same as PRP. Dextrose Prolotherapy uses a glucose-based solution. PRP is prepared from the patient’s blood and contains a concentration of platelets and signaling proteins. The treatments have different preparations, proposed mechanisms, costs, and evidence bases. Patients can read more about H3 Prolotherapy and platelet-rich plasma treatment on our website.
The Caring Medical meniscus Prolotherapy study
In 2010, we published a retrospective case series involving 24 patients and 28 knees with meniscal pathology documented by MRI. Patients received an average of six Prolotherapy visits and were followed for an average of 18 months after their final treatment. Reported mean pain scores decreased from 7.2 to 1.6, and stiffness scores decreased from 6.0 to 1.8. Patients also reported improvements in walking, exercise ability, range of motion, and other measures; 27 of 28 treated knees met the patients’ expectations, and one knee proceeded to surgery. (7)
These observations were encouraging, but the study has major limitations. It was small and retrospective, had no control group or blinding, relied substantially on patient-reported outcomes, and did not establish meniscal healing with standardized follow-up imaging or arthroscopy. Patients also received individualized injections, making it difficult to identify which component of treatment produced improvement. Consequently, the study can support further investigation and shared decision-making, but it cannot prove that Prolotherapy repairs meniscal tissue or is superior to rehabilitation, placebo injection, PRP, or surgery.
This is an important update from the original article. We no longer believe that this case series alone justifies calling Prolotherapy first-line treatment for every meniscal tear. The first-line plan should be individualized and should usually include appropriate rehabilitation, while urgent or repairable tears should be evaluated surgically.
What newer research says about dextrose Prolotherapy
Most modern dextrose Prolotherapy studies involve symptomatic knee osteoarthritis rather than isolated meniscal tears. A 2024 systematic review and meta-analysis found improvements in pain and function after dextrose Prolotherapy, but the authors also reported substantial variation among studies and limitations in the evidence. (8) A 2023 systematic review similarly concluded that Prolotherapy may improve pain and function in osteoarthritis, while emphasizing heterogeneity and the need for better-quality trials. (9)
This distinction matters. Osteoarthritis studies may be relevant when a patient has a degenerative tear within an arthritic knee, but improvement in knee pain does not demonstrate that a torn meniscus has structurally healed. It may reflect effects on pain signaling, inflammation, capsular or ligamentous structures, or the joint environment. Direct controlled trials of dextrose Prolotherapy for well-characterized meniscus tears remain lacking.
What newer research says about PRP for meniscus tears
PRP has attracted interest because platelets release signaling proteins involved in tissue repair. It has been studied as a nonsurgical injection and as an adjunct to surgical meniscus repair.
A 2024 systematic review of PRP used without surgery for degenerative meniscal tears found that patients often reported improvement, but the included studies were heterogeneous and generally had low levels of evidence. Imaging results were inconsistent, and the review could not establish a standardized preparation, dose, injection location, or treatment schedule. (10)
Another 2024 systematic review reached a similarly cautious conclusion: clinical and imaging outcomes varied, and limitations in study design made it difficult to determine whether PRP reliably heals degenerative tears. (11)
PRP may therefore be discussed as an option for selected patients, particularly when symptoms persist despite rehabilitation and the goal is to pursue a nonsurgical approach. It should not be presented as proven meniscus regeneration. Patients interested in cellular procedures can also review our evidence discussion about stem-cell therapy for knee meniscus tears and post-meniscectomy pain.
Who might be considered for an injection-based treatment?
An injection consultation may be reasonable for a patient who:
- Has knee pain and examination findings that correlate with meniscal or associated ligament/capsular pathology.
- Has completed an appropriate rehabilitation program but remains limited.
- Has a degenerative tear with coexisting osteoarthritis and understands that pain relief is more strongly studied than structural meniscal healing.
- Has instability or pain arising from supporting soft tissues that may be relevant treatment targets.
- Wants to explore nonsurgical options after reviewing their benefits, limitations, costs, and alternatives.
An injection is less likely to be an appropriate substitute for surgical evaluation when there is a displaced bucket-handle tear, true locked knee, repairable acute tear in a young patient, significant root tear, fracture, infection, major ligament injury, or rapidly worsening neurological or vascular symptoms.
Summary
Meniscus tears require individualized care. An MRI finding alone does not determine the source of pain or the correct treatment. For many degenerative tears, structured exercise-based therapy is the best-supported first-line approach. When surgery is necessary, preserving and repairing meniscal tissue is generally preferred when feasible.
At Caring Medical, we evaluate how the meniscus interacts with the ligaments, capsule, cartilage, alignment, and movement of the entire knee. Dextrose Prolotherapy or PRP may be considered for selected patients, particularly when associated instability or osteoarthritis is present and conservative care has not restored function. However, patients should understand that the evidence for these injections is stronger for symptom improvement in knee osteoarthritis than for proven structural healing of an isolated meniscus tear.
Our 2010 case series reported meaningful improvement in a small group of patients, but it does not establish efficacy by itself. Larger, controlled studies using clearly defined tear types, standardized treatment protocols, functional outcomes, and follow-up imaging are needed.
Medical disclaimer: This article is for educational purposes only and is not a substitute for diagnosis or treatment by a qualified healthcare professional. Treatment decisions should be based on an individual history, examination, imaging when appropriate, goals, and a discussion of reasonable alternatives. Injection treatments carry risks and may not be appropriate for every patient.
References
1 Englund M, Guermazi A, Gale D, Hunter DJ, Aliabadi P, Clancy M, Felson DT. Incidental meniscal findings on knee MRI in middle-aged and elderly persons. N Engl J Med. 2008;359(11):1108-1115. [Google Scholar]
2 Migliorini F, Schäfer L, Bell A, Weber CD, Vecchio G, Maffulli N. Meniscectomy is associated with a higher rate of osteoarthritis compared to meniscal repair following acute tears: a meta-analysis. Knee Surg Sports Traumatol Arthrosc. 2023;31(12):5485-5495. [Google Scholar]
3 Prill R, Ma CB, Wong SE, et al. The formal EU-US Meniscus Rehabilitation 2024 Consensus: An ESSKA-AOSSM-AASPT initiative. Part II—Prevention, non-operative treatment and return to sport. Knee Surg Sports Traumatol Arthrosc. 2025;33(8):3014-3024. [Google Scholar]
4 Noorduyn JCA, van de Graaf VA, Willigenburg NW, et al. Effect of physical therapy vs arthroscopic partial meniscectomy in people with degenerative meniscal tears: five-year follow-up of the ESCAPE randomized clinical trial. JAMA Netw Open. 2022;5(7). [Google Scholar]
5 Meng J, Tang H, Xiao Y, et al. Long-term effects of exercise therapy versus arthroscopic partial meniscectomy for degenerative meniscal tear: a meta-analysis of randomized controlled trials. Asian J Surg. 2024;47(6):2566-2573. [Google Scholar]
6 Sihvonen R, Paavola M, Malmivaara A, et al. Arthroscopic partial meniscectomy versus sham surgery for a degenerative meniscal tear. N Engl J Med. 2013;369(26):2515-2524. [Google Scholar]
7 Hauser RA, Phillips HJ, Maddela HS. The case for utilizing Prolotherapy as first-line treatment for meniscal pathology: a retrospective study shows Prolotherapy is effective in the treatment of MRI-documented meniscal tears and degeneration. Journal of Prolotherapy. 2010;2(3):416-437. [Google Scholar]
8 Khateri S, Nejad FB, Kazemi F, et al. The effect of dextrose prolotherapy on patients diagnosed with knee osteoarthritis: a comprehensive systematic review and meta-analysis of interventional studies. Health Sci Rep. 2024;7(6). [Google Scholar]
9 Waluyo Y, Artika SR, Wahyuni IN, Gunawan AMAK, Zainal ATF. Efficacy of prolotherapy for osteoarthritis: a systematic review. J Rehabil Med. 2023;55. [Google Scholar]
10 Elphingstone JW, Alston ET, Colorado BS. Platelet-rich plasma for nonoperative management of degenerative meniscal tears: a systematic review. J Orthop. 2024;54:67-75. [Google Scholar]
11 Gopinatth V, Batra AK, Chahla J, et al. Degenerative meniscus tears treated nonoperatively with platelet-rich plasma yield variable clinical and imaging outcomes: a systematic review. Arthrosc Sports Med Rehabil. 2024;6(2):100916. [Google Scholar]